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Abstract
CD38, a type II transmembrane glycoprotein expressed in many cells of the immune system, is involved in cell signaling,
migration and differentiation. Studies in CD38 deficient mice (CD38 KO mice) indicate that this molecule controls
inflammatory immune responses, although its involvement in these responses depends on the disease model analyzed.
Here, we explored the role of CD38 in the control of autoimmune responses using chicken collagen type II (col II)
immunized C57BL/6-CD38 KO mice as a model of collagen-induced arthritis (CIA). We demonstrate that CD38 KO mice
develop an attenuated CIA that is accompanied by a limited joint induction of IL-1b and IL-6 expression, by the lack of
induction of IFNc expression in the joints and by a reduction in the percentages of invariant NKT (iNKT) cells in the spleen.
Immunized CD38 KO mice produce high levels of circulating IgG1 and low of IgG2a anti-col II antibodies in association with
reduced percentages of Th1 cells in the draining lymph nodes. Altogether, our results show that CD38 participates in the
pathogenesis of CIA controlling the number of iNKT cells and promoting Th1 inflammatory responses.
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Introduction
The nicotinamide adenine dinucleotide (NAD+) glycohydrolase
CD38 (EC 3.2.2.5) is a type II transmembrane glycoprotein widely
expressed in many cell population of the immune system,
including B and T cells, NK cells, circulating monocytes and
DC as well as in non-hematopoietic cells [1,2]. This molecule acts
as an ectoenzyme that catalyzes the formation of adenosine
diphosphate ribose (ADPR), cyclic ADPR (cADPR), and nicotin-
amide from NAD+ under neutral pH; or nicotinic acid adenine
dinucleotide phosphate (NAADP+) from NADP+ under acidic
conditions [1–5]. Both cADPR and NAADP+ are potent
endogenous activators of intracellular Ca2+ release and function
as signaling molecules in leukocytes and other CD38 expressing
non-hematopoietic cells [6]. In addition to its ectoenzyme activity,
CD38 can also function as a plasma membrane signaling receptor
in leukocytes [2,7] interacting with CD31/PECAM-1 expressed
by endothelial cells and other cell lineages. This interaction
promotes leukocyte proliferation, T cell activation, monocyte-
derived DC maturation, survival and migration and induces Th1
polarization in co-cultures of DC with CD4+ T lymphocytes [8–
10]. In this regard, our studies indicate that CD38 is located in
privileged sites for signaling and cell-communication such as
membrane rafts, immunological synapse, recycling endosomes,
and exosomes [10–13]. Moreover, CD38 signaling potential varies
depending upon the cellular context and its physical and/or
functional association with other signaling molecules [10,12,13].
Studies in CD38 deficient mice (CD38 KO mice) highlight the
importance of this molecule for the appropriated functioning of
the immune system. CD38 deficiency has been associated with
defects in humoral B-cell responses [14,15], neutrophil migration
[16] and DC trafficking [15]. In CD38 KO mice, the numbers of
peripheral Tregs and invariant NKT (iNKT) cells are reduced as a
result of a NAD+-induced cell death process [17,18]. The
extracellular accumulation of NAD+ occurring in these mice
induces the ADP ribosyltransferase-2 (ART-2)-mediated ADP-
ribosylation of the P2X7 purinergic receptor and its ATP-
independent activation which initiates the apoptotic process
[19]. Thus, CD38 acts as a critical regulator of inflammatory
and innate immune responses and CD38 deficiency in NOD mice
accelerates the development of type I diabetes (T1D) [17]. In
NOD mice activation of iNKT cells with the superagonist alpha-
galactosylceramide leads to differentiation of tolerogenic DC,
which inhibits the development of T1D [18]. In contrast, in the
absence of CD38, ART-2 preferentially activates apoptotic
deletion of CD4+ iNKT cells and accelerates T1D onset [18].
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However, it should be stressed that iNKT cells through the
production of IL-17 may also have pro-inflammatory effects as
occurs during the development of collagen type II-induced
arthritis (CIA) where mice deficient or depleted in such cells
develop an attenuated form of disease [20,21]. Moreover,
activation of iNKT cells in the C57BL/6 (B6) background, unlike
in the NOD genetic background, has an adjuvant-like effect that
enhances various immunological responses including the down-
stream differentiation of non-tolerogenic DCs [22]. In this regard,
CD38 KO mice in the B6 genetic background develop milder
inflammatory lesions in a model of post-ischemic inflammation
and brain injury after temporary middle cerebral artery occlusion,
although a direct relationship between this protective effect and
changes in iNKT cells has not been established [23]. Inflamma-
tory responses and airway hyperreactivity are also attenuated in
allergen-challenged CD38 KO mice [24,25]. Moreover, in SLE
patients increased numbers of CD38+ B cells have been observed
and in patients with active disease, B cells expressing high levels of
CD38 produce IgG anti-dsDNA autoantibodies [26].
Based in these apparently conflicting results, in the present study
we have explored the contribution of CD38 to the control of
autoimmunity using the experimental model of collagen type II (col
II)-induced arthritis (CIA) in CD38 KO mice. We demonstrate here
that in comparison to WT mice, CD38 KO mice develop an
attenuated form of CIA in association with lower percentages of
iNKT cells and a down-modulation in Th1 immune responses.
Results
Development of an attenuated CIA in CD38 KO mice
In the present study we explored whether the deficiency in
CD38 influenced the clinical progression of CIA in B6 mice. To
this end, we immunized WT and CD38 KO mice with chicken col
II-CFA. The cumulative incidence of CIA was slightly, although
not significantly, lowers in CD38 KO mice than in WT mice
(Figure 1A). However, the clinical severity of CIA was also lower in
CD38 KO mice than in WT mice (Figure 1B). To further analyze
the degree of paw inflammation during CIA development, the
thickness of the paws at the level of the metacarpus and metatarsus
was measured with a digital caliper 7 weeks after col II-
immunization. A 90% of WT mice (19/21 mice) exhibited a
significant inflammation of the paws (inflammation values higher
than the mean 6 3SD of those found in non-immunized controls),
whereas only 30% (6/20 mice) of col II-immunized CD38 KO
mice showed signs of paw inflammation (Figure 1C). In correlation
with the clinical findings, the severity of every individual
radiological sign considered here (soft tissue swelling, juxtaarticular
osteopenia, narrowing or disappearance of the interosseous spaces
reflecting cartilage loss and bone irregularities secondary to
periosteal new bone formation and/or marginal articular erosions)
was significantly lower in CD38 KO than in WT mice (Figure 2A
and B). The histological analyses of the joints in CD38 KO mice
failed to show signs of cartilage destruction although showed the
presence of synovitis and pannus formation (Figure 2C). All these
lesions were present in WT mice (Figure 2C).
Reduced number of iNKTs and lack of involvement of
Tregs in the protection against CIA of CD38 KO mice
It has been reported that Tregs are very susceptible to the pro-
apoptotic effects of extracellular NAD+ and accordingly, CD38
KO mice exhibit low numbers of this cell population [17]. In
agreement with these results, the number of lymph node Tregs in
our non-immunized CD38 KO mice were significantly lower than
in WT mice (Figure 3A). However, this cell population increased
to similar levels in both CD38 KO and WT mice after col II
immunization (Figure 3A).
We then explored whether the increase in the number of Tregs after
the immunization with col II-CFA in CD38 KO mice was involved in
the protection against CIA. To this end, groups of WT and CD38 KO
mice were either depleted in Tregs with a citotoxic anti-CD25 mAb or
treated with PBS as a control, prior to the induction of CIA. Again, the
severity of CIA was lower in PBS-treated CD38 KO than in PBS-
treated WT mice and this severity did not increase after depletion of
Tregs in both groups of mice (Figure 3B).
Similarly to Tregs, iNKT cells are also very susceptible to the
pro-apoptotic effects of extracellular NAD+ [18]. In this regard,
the number of iNKT cells in the spleen of non-immunized CD38
KO mice was severely reduced in comparison to WT mice
(Figure 3C). However, unlike Tregs, the immunization with col II-
CFA induced a significant increase of iNKT cells in WT, but not
in CD38 KO mice (Figure 3C).
Altered anti-col II antibody production in CD38 KO mice
The intensity and quality of anti-col II humoral immune
responses was compared between col II-immunized CD38 KO
and WT mice by analyzing the levels of circulating IgG1 and
IgG2a anti-col II antibodies. Both groups of mice exhibited strong
anti-col II antibody responses 3 and 6 weeks after CIA-induction
(Figure 4). However, qualitative differences in these antibody
responses were observed between CD38 KO and WT mice. Thus,
serum levels of IgG1 anti-col II antibodies were significantly
higher at both 3 and 6 weeks after immunization in CD38 KO
mice as compared with those in WT mice. In contrast, the levels of
IgG2a anti-col II antibodies were significantly higher in WT than
in CD38 KO mice at 6 weeks upon immunization, whereas the
differences were not statistically significant at the onset of the
disease (Figure 4), suggesting that CD38 KO mice show an altered
Th1/Th2 balance in response to col II immunization.
Reduced joint expression of pro-inflammatory cytokines
and altered Th1 cytokine pattern in CD38 KO mice
The reduced severity of CIA in CD38 KO mice together with the
altered anti-col II antibody responses compared to WT mice,
prompted us to explore by quantitative real time RT-PCR the
pattern of cytokine expression in the joints during the induction of
CIA in these strains of mice. As expected [27], a significant increase
in the expression of the arthritogenic IL-1b, TNFa and IL-6
transcripts was observed in the joints of WT mice 7 weeks after
immunization with col II-CFA (Figure 5). In addition, joint levels of
TGFb1, IL-10, IFNc, IL-4 and IL-17 mRNAs were augmented in
WT mice with arthritis (Figure 5). In parallel with the clinical,
radiological and histological findings, the expression of IL-1b and
IL-6, but not of TNFa was reduced in the joints of col II-immunized
CD38 KO mice (Figure 5). The reduced severity of CIA in CD38
KO mice was not accompanied by an increased joint expression of
the TGFb1 and IL-10 inhibitory cytokines (Figure 5). Unlike WT
mice, the expression of IFNc, the prototypical Th1 cytokine, was
not induced in the joints of CD38 KO mice after CIA induction
(Figure 5) Although the differences were not statistically significant,
the induction in the expression of IL-4 and IL-17 and in the joints of
CD38 KO mice was higher and lower, respectively, than the
observed in WT mice (Figure 5).
Differential induction of Th1, but not Th17 cells after CIA
induction in CD38 KO and WT mice
Due to the pattern of cytokine expression in the joints and to
further explore the mechanisms implicated in the amelioration of
CD38 Deficiency Ameliorates CIA
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CIA in CD38 KO mice, we compared the number of different
functional CD4+ T-cell subpopulations in the draining lymph
nodes of WT and CD38 KO mice before and after immunization
with col II-CFA. Both IFNc-producing Th1 and IL-17-producing
Th17 cell populations were augmented in the paraaortic lymph
nodes of WT mice 3 weeks after immunization with col II-CFA
(Figure 6). A similar increase in the number of Th17 cells was
observed in CD38 KO mice. Although the number of CD4+IFNc
Th1 cells in the draining lymph nodes of immunized CD38 KO
mice was also higher than in non-immunized mice, such an
increase was significantly lower than the observed in immunized
WT mice in correlation with the reduced IFNc expression in the
joints and of circulating IgG2a anti-col II antibody responses
(Figure 6).
Discussion
Different studies in experimental murine models of inflamma-
tory/autoimmune diseases reveal some discrepancies about the
role of CD38 in the control of pathological immune responses
[17,18,23–26]. Here, we extend these previous observations by
analyzing the contribution of CD38 to the pathogenesis of CIA, a
paradigmatic model of autoimmune disease mediated by Th1 and
Th17 lymphocytes. Our results show that the severity of CIA in
CD38 KO mice is lower than in WT mice. These results clearly
contrast with the development of accelerated diabetes in NOD
mice deficient in CD38, partly because of a loss of iNKT cells and
Tregs [17,18] that are highly sensitive to NAD-induced cell death
activated by ART-2-mediated ADP ribosylation of P2X7
receptors [19]. However, after immunization of CD38 KO mice
with col II-CFA, the number of Tregs reaches that of immunized
WT mice. Although the reasons for the increase in Treg observed
in immunized CD38 KO mice are not clear yet, the experiments
in animals depleted in these cells after treatment with a cytotoxic
anti-CD25 mAb clearly indicate that this regulatory T cell
population does not play a role in the protection against CIA
observed in such mice. One intriguing finding in our study is the
lack of exacerbation of CIA in Treg-depleted WT mice which
contrasts with the increase in arthritis severity after anti-CD25
treatment observed by others [28,29]. However, these discrepan-
cies can be attributed to the different models of inflammatory
arthritis used in these studies and/or to the different timing of anti-
CD25 mAb administration during the development of the disease.
In this regard, in our study the anti-CD25 treatment is
administered once prior to the induction of CIA instead of the 4
weeks-long treatment initiated 13 days after col II-immunization
used by Kelchtermans et al [28]. In addition, the treatment
protocol used here has been proved to be able to reverse the
Figure 1. Involvement of CD38 in the development of CIA. (A) Cumulative incidence of CIA. Results are expressed as the mean 6 SD of the
percentage of affected mice at the indicated weeks after immunization. (B) Clinical severity of CIA at different periods after immunization with col II-
CFA. Results are expressed as the mean 6 SD of the clinical score in each mouse. (C) Paw inflammation was measured 7 weeks after immunization
using a digital caliper. The mean values of the inflammation in the four paws of every individual mouse are expressed. Solid bars represent the mean
value of each examination. Dotted bars represent the mean 6 3SD of the values found in their respective non-immunized control groups. Statistic
differences between WT and CD38 KO mice are indicated as follow: *p,0.05, **p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0033534.g001
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protection against CIA in transgenic mice overexpressing human
Bcl-2 in T cells [30], further indicating that the lack of
exacerbation of CIA in Treg-depleted WT mice is not related to
the concomitant possible depletion of pathogenic CD4 cells
expressing transitory CD25 after their activation.
Similarly to Tregs, the number of iNKT cells, that also possess
regulatory properties in certain models of autoimmune diseases, is
also reduced in CD38 KO mice [18]. This reduction has been
involved in the acceleration and aggravation of T1D in NOD mice
[17]. However, iNKT cells through the production of IL-17
promote CIA development and mice deficient or depleted in such
cells develop an attenuated form of disease resembling that of our
B6 CD38 KO mice [20,21]. Moreover, activation of iNKT cells in
the B6 background, unlike in the NOD genetic background, has
an adjuvant-like effect that enhances various immunological
responses including the downstream differentiation of non-
Figure 2. Reduced radiological and histological lesions in CIA developing CD38 KO mice. 8–12 weeks-old WT and CD38 KO male mice
were immunized with col II-CFA. (A) Representative radiological images of the front paws of WT and CD38 KO mice, non-immunized and 7 weeks
after immunization with col II-CFA. (B) Radiological score of four individual signs. Results are expressed as the values of individual mice. Bars represent
the mean value of each examination. Statistic differences are indicated as follow: *p,0.05, **p,0.01. (C) Representative histological appearance of
the joints (610) of WT and CD38 KO mice non-immunized and 7 weeks after immunization with col II-CFA. Signs of cartilage and/or bone destruction
(arrows), sinovitis (arrow head) and pannus (*) are indicated.
doi:10.1371/journal.pone.0033534.g002
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tolerogenic DCs [22]. It is, therefore, likely that the reduction in
the number of iNKT cells observed in CD38 KO mice, that are
not recovered during CIA development, eventually contribute to
the development of a mild arthritis in CD38 KO. According to
this possibility, the consequences of CD38 deficiency in the
acceleration or attenuation of different inflammatory processes
may be in part related to the respective anti- or pro-inflamatory
role of iNKT cells in such diseases.
The development of an attenuated CIA in CD38 KO mice can
be also related with the capacity of CD38 to regulate the migration
of DC precursors from the blood to peripheral sites as well as the
migration of mature DCs to lymph nodes in response to CCL2,
CCL19, CCL21, and CXCL12 chemokines [15] affecting in that
way the correct priming of CD4+ T cells. In addition, considering
that cADPR and NAADP+ are potent endogenous activators of
intracellular Ca2+ release [6], the deficiency of CD38 may impairs
the activation of T cells. In this regard, CD38 KO mice immunized
with low doses of T-dependent antigens precipitated with alum,
mount poor IgG1 antigen specific humoral immune responses [15].
However, the development in col II-immunized CD38 KO mice of
strong collagen-specific humoral immune responses and the
induction of a similar Th17 response than the observed in WT
mice argues against the possibility of poor T-cell priming as the
cause of the attenuated CIA in these CD38 deficient mice.
Studies performed in animals immunologically depleted or
genetically deficient in B cells underlined the importance of humoral
immune responses in the induction of CIA [31,32]. Strikingly, CD38
KO mice developing a less severe CIA than WT mice, exhibited
higher serum levels of IgG1 and lower levels of IgG2a, anti-col II
antibodies. The increase in the levels of IgG1 anti-col II antibodies
observed in immunized CD38 KO mice contrasted with a previous
report showing an impaired IgG1 humoral immune responses against
T-dependent antigens in these mutant mice [15]. This discrepancy
was probably attributed to the different immunization regimen used
in both studies; the protocol used here for the induction of CIA
required the use of high doses of col II emulsified in a mycobacterium
tuberculosis enriched CFA instead of the immunization with very low
doses of antigen precipitated with alum used in the former study. In
fact, a direct comparison of humoral immune responses in CD38 KO
mice reveals that the intensity of IgG1 immune responses, but not of
IgG2a, IgG2b, IgG3 and IgA humoral responses, to T-dependent
antigens was highly dependent on both the dose of the antigen and
the adjuvant employed in the immunization protocol [14]. Studies
addressing the pathogenic activity of autoantibodies revealed the
importance of the IgG subclass in their capacity to promote tissue
injury. Thus, it was demonstrated that the IgG2a switch variant of an
anti-red blood cell autoantibody had about 20 times more pathogenic
potential than the IgG1 switch variant [33], in clear correlation with
the different affinities of IgG2a and IgG1 antibodies for Fcc receptors
promoting antibody-dependent cellular cytotoxicity [34] and with the
higher capacity of IgG2a antibodies to activate the complement
cascade [35]. In addition to the possible differential ability to promote
tissue injury, the changes in the levels of circulating IgG1 and IgG2a
anti-col II antibodies observed in CD38 KO mice compared to WT
mice indirectly reflected a distinct pattern of functional CD4+ T cell
differentiation between both strains of mice after col II immunization.
Whereas the pathogenic role of Th17 cells in the development
of CIA has been clearly defined [36,37], the contribution of Th1
cells is less clear. Thus, IFNa˜ deficiency renders the normally
resistant B6 strain susceptible to disease [38,39], and lack of IFNa˜
or signalling through the IFNa˜ receptor enhances the severity of
arthritis in susceptible strains such as DBA/1 [40,41]. On the
other hand, enhanced Th1 and Th17 immune responses are
observed in experimental situations associated to exacerbated
CIA, such as in mice with a deficiency of myeloid cell-specific IL-1
receptor antagonist or mice deficient in ApoE lipoprotein [42,43].
In agreement with these last observations, joint expression of IFNa˜
in col II immunized CD38 KO mice is similar to that of non-
immunized controls and the induction of Th1 lymphocytes in the
draining lymph nodes of these mice is significantly lower than in
col II immunized WT mice. The contribution of CD38 to Th1
differentiation has been demonstrated previously. Disruption of
CD38/CD31 interaction by soluble CD38 in LPS-stimulated
monocyte-derived DC, co-cultured with naı¨ve T cells, inhibits the
release of IFNa˜ by T cell and impairs Th1 polarization [8]. In
addition, the absence of CD38 renders mice more susceptible to
mycobacterial avium infection secondary to an ineffective Th1
differentiation and polarization, which is essential for the control
of mycobacterial avium infection [9]. An additional mechanism
accounting for the reduced CIA severity in CD38 KO mice is
most likely related to the deficient induction of several arthrito-
genic cytokines in the joints such as IL-1b and IL-6 although the
Figure 3. Lack of involvement of Tregs in the reduced CIA of
CD38 KO mice. (A) Number of Tregs in the lymph nodes of WT and
CD38 KO mice non-immunized (NI; N) and 3 weeks after immunization
with col-II-CFA (#). Representative results of 3 independent experi-
ments are expressed as the values of individual mice. Bars represent the
mean value of each examination. (B) Clinical severity of CIA 7 weeks
after immunization with col II-CFA in PBS-treated or Treg-depleted WT
and CD38 KO mice Representative results of 2 independent experi-
ments are expressed as the values of individual mice are expressed. Bars
represent the mean value of each examination. C) Number of iNKT cells
in the spleen of WT mice and CD38 KO mice before (day 0) and 15 and
30 days after col II immunization. Results are expressed as mean 6 SD.
Statistic differences are indicated as follow: ns: non-significant, *p,0.05,
**p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0033534.g003
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Figure 4. Serum levels of IgG1 and IgG2a anti-col II antibodies before, 3 and 8 weeks after immunization with col II-CFA. Values of
individual mice are expressed. Bars represent the mean value of each examination. Statistic differences are indicated as follow: *p,0.05, **p,0.01,
***p,0.001.
doi:10.1371/journal.pone.0033534.g004
Figure 5. Cytokine expression pattern in the joints of WT and CD38 KOmice during CIA development. Analysis by quantitative real-time
RT-PCR of mRNA from different cytokines in the paws of WT and CD38 KO mice, non-immunized (open bars) and 7 weeks after immunization with col
II-CFA (closed bars). Results from three independent experiments (15–20 animals/group) are expressed as mean 6 SD fold change of each cytokine
relative to GAPDH expression measured in parallel in each sample. Statistic differences are indicated as follow: ns: non-significant, *p,0.05, **p,0.01,
*** p,0.001.
doi:10.1371/journal.pone.0033534.g005
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joint expression of TNFa is similar in both groups of CIA-
developing mice.
All together, the data presented here underline the importance of
CD38 in the pathogenesis of CIA probably by increasing the
percentages of iNKT cells and by promoting the development of Th1
inflammatory responses. These results can be useful for the design of
new therapeutic strategies for rheumatoid arthritis in humans.
Materials and Methods
Ethics Statement
All studies with live animals were approved by the Universidad
de Cantabria Institutional Laboratory Animal Care and Use
Committee in compliance with the Guide for the Care and Use of
Laboratory Animals (ILAR, 1985).
Mice
B6 WT mice were purchased from Harlan Iberica (Barcelona,
Spain). CD30 KO mice were backcrossed onto the B6 background
for more than 12 generations, as described previously [14]. Mice
were bled from the retro-orbital plexus 3 and 6 weeks after
immunization.
Induction and assessment of arthritis and serological
studies
Chicken col II (Sigma, St Louis, MO) was dissolved at a
concentration of 2 mg/ml in 0.05 M acetic acid and emulsified with
CFA containing 4 mg/ml of Mycobacterium tuberculosis (MD Bioprod-
ucts, Zu¨rich, Switzerland). For the induction of CIA, 8–12 weeks-old
male mice were immunized once at the base of the tail with 150 mg of
antigen in a final volume of 150 ml. The in vivo depletion of Tregs was
Figure 6. Expansion of Th17 but not and Th1 cells in the draining lymph nodes of col II-immunized CD38 KO mice. WT and CD38 KO
mice male mice were immunized with col II-CFA. For intracellular cytokine staining, lymphocytes from paraaortic lymph nodes were stimulated 3
weeks after immunization with phorbol myristate acetate and ionomycin in the presence of GolgiStop solution. (A) Representative histograms of
CD4+IFNc+ Th1 and CD4+IL-17+ Th17 cells, determined by flow cytometry, in the different experimental groups. The percentage of each population is
indicated. (B) Number of CD4+IFNc+ Th1 (left panel) and CD4+IL-17+ Th17 (right panel) cells in the draining lymph nodes of non-immunized (NI; N)
and 3 weeks post-immunized (#) mice. Values of individual mice are expressed. Bars represent the mean value of each examination. Statistic
differences are indicated as follow: ns: non-significant, *p,0.05, **p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0033534.g006
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performed using an anti-CD25 mAb (PC61: rat IgG1). Mice received
a single injection of 2.5 mg of anti-CD25 mAb or PBS as controls, 4
days prior the immunization with col II. The efficiency of this
treatment was evaluated in peripheral blood mononuclear cells by
flow cytometry the one day before immunization. Previous studies
showed that this treatment was able to reverse the protection against
CIA in transgenic mice overexpressing human Bcl-2 in T cells [30].
An evaluation of arthritis severity was performed weekly. Clinical
severity was quantified according to a graded scale of 0–3 as follows:
0 = no inflammation (normal joint); 1 = detectable local swelling and/
or erythema; 2 = swelling in.1 joint and pronounced inflammation;
3 = swelling of the entire paw and/or ankylosis. Each paw was
graded, and the scores were summed (with a maximum possible score
12 per mouse). In addition, the inflammation of the paws was
measured at the level of metacarpus and metatarsus 7 weeks after
immunization using a digital caliper (Somet CZ, Bilina, Czech
Republic).
Radiological studies were performed using a CCX Rx ray
source of 70 Kw with an exposition of 90 ms (Trophy Irix X-Ray
System; Kodak Spain, Madrid) and Trophy RVG Digital
Imagining system as previously described [42]. Radiological
images were scale graded according to the presence of 4 different
radiological lesions (1: soft tissue swelling, 2: juxtaarticular
osteopenia due to alterations in bone density, 3: joint space
narrowing or disappearance and 4: bone surface irregularities due
to marginal erosions and/or periosteal new bone formation). The
extension of every individual lesion in each paw (local: affecting
one digit or one joint in the carpus; diffuse: affecting two or more
digits and/or two or more joints in the carpus) was graded from 0
to 2 as follow: 0: absence; 1: local; 2: diffuse.
Mice were killed 7 weeks after immunization and the hind paws
were fixed in 10% phosphate-buffered formaldehyde solution,
decalcified in Parengy’s decalcification solution overnight. The tissue
was then embedded in paraffin. Sections (5 mm) were stained with
hematoxylin and eosin and examined in a light-phase microscope.
Serum levels of IgG1 and IgG2a anti-col II antibodies were
measured by ELISA as described [44]. The assays were developed
with anti-mouse IgG subclass specific antibodies conjugated to
alkaline phosphatase (Sigma). Results were expressed in Absor-
bance Units at 405 nm.
Flow cytometry studies
According to the route of immunization (the base of the tail), the
paraaortic lymph nodes were used as draining lymph nodes [45].
As expected, the size of these draining lymph nodes was greatly
enlarged in both groups of mice after immunization with col II-
CFA (number of paraaortic lymph node cells in WT mice before:
0.960.26106, and after immunization with col II-CFA:
5.960.36106; number of paraaortic lymph node cells in CD38
KO mice before: 1.260.16106, and after immunization with col
II-CFA: 6.360.46106). The number of Tregs, Th1 and Th17 cells
in the draining lymph nodes of WT and CD38 KO mice before
and 3 or 7 weeks after immunization with col II-CFA were
determined by flow cytometry, as described previously [42].
Briefly, intracellular cytokine staining was performed using an
intracellular staining kit (BD Biosciences). Lymphocytes were
stimulated with PMA (50 ng/ml) and ionomycin (750 ng/ml) in
the presence of GolgiStop solution (BD Biosciences) for 6 hours
and stained with FITC–conjugated anti-CD4 and PE-conjugated
anti-IFNa˜ or PE-conjugated anti–IL-17 (all antibodies from BD
Biosciences). A PE-conjugated IgG2a irrelevant antibody was used
as an isotype control of cytokine staining. Since in our non-
immunized mice iNKT cells were almost undetectable in the
paraaortic lymph nodes, the evaluation of iNKT cells was
performed in the spleen at different time points after col II
immunization. Cells were stained with PE-conjugated CD1d
tetramers loaded with a-galactosylceramide (ProImmune, Oxford
Science Park, UK) according to the manufacturer guidelines,
FITC–conjugated anti-CD3 and allophycocyanin-conjugated
CD19. The CD1d restricted iNKT cell population was identified
as CD192CD3+CD1d-tetramer-a-galactosylceramide+ cells. A
total of 56104 viable cells were analyzed in a FACSCanto II flow
cytometer using FACSDiva software (BD Biosciences).
Quantitative real-time RT-PCR analyses
Total RNA was obtained from joints by TRIzol extraction
(Invitrogen, Life Technologies Corporation, Carlsbad, CA). One
mg of the isolated RNA was used for cDNA synthesis with a RT-
PCR kit (Amersham Pharmacia Biotech, Piscataway, NJ),
according to the manufacturer instructions. Quantitative real time
RT-PCR was performed on a MX-3000P Stratagene instrument
(Agilent Technologies, Inc., Santa Clara, CA) using specific
TaqMan expression assays and universal PCR Master Mix
(Applied Biosystems, Life Technologies Corporation). The follow-
ing TaqMan expression assays were used in our study:
Mm00434228_m1 (IL-1b), Mm00445259_m1 (IL-4), Mm0044
6190_m1 (IL-6), Mm00439616_m1 (IL-10), Mm00439619_m1
(IL-17A), Mm00443258_m1 (TNFa´), Mm00801778_m1 (IFNa˜)
and Mm00441724_m1 (TGFb). Results (in triplicate) were
normalized to GAPDH expression and measured in parallel in
each sample. Data were expressed as mean fold change relative to
control samples.
Statistical analysis
Statistical analysis of differences between groups of mice was
performed using the Mann-Whitney and Two-Way Anova test.
Probability values ,0.05 were considered significant.
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